Visual Snow Syndrome: What’s Next in Research?

November 16, 2026 – New research into visual processing, brain activity and the biology of Visual Snow Syndrome is raising important questions. But which developments represent genuine progress, and which studies are open to participants? We examine the latest research, what it could mean for patients and where to find out more.

Why does visual snow remain constantly visible? Could the brains of people with Visual Snow Syndrome (VSS) process visual information differently? And might scientists eventually identify measurable neurological changes that could help improve diagnosis or guide treatment?

These questions are at the centre of several research projects currently taking place internationally.

In London, scientists are investigating how the brain filters visual information, using experiments that include augmented reality. In Minnesota, researchers are examining visual adaptation and its relationship to brain activity. Meanwhile, another team at King’s College London has completed data collection for a study investigating whether VSS has a distinct pattern of neurological activity.

For people living with VSS, however, the significance of these studies is not always immediately clear. Some investigate possible mechanisms behind the condition, while others explore methods that could eventually improve diagnosis. None of the studies discussed here has established a cure or a proven new treatment.

There are also practical limitations. Many research projects require participants to travel to specialised facilities, sometimes abroad. Others have strict eligibility requirements or are no longer recruiting. For patients whose symptoms significantly restrict their ability to travel, participation may not be realistic.

So what is actually happening in VSS research in 2026, and which developments deserve attention?

1. London: Can scientists measure how the brain filters visual noise?

King’s College London, United Kingdom

One of the more recent opportunities for patients to contribute to research is the VISIONS study at King’s College London.

The project investigates how people with VSS process visual information, particularly how the brain filters visual noise.

Under normal circumstances, the visual system continuously processes and prioritises information. Researchers are interested in whether aspects of this processing differ in people who experience persistent visual snow.

The study uses computer-based visual tasks involving moving patterns. Participants with VSS also use augmented reality (AR) to adjust a simulation of visual snow until it resembles their own experience.

This is particularly interesting because visual snow is inherently subjective. Two people may describe similar symptoms while experiencing them differently. Developing methods to characterise these experiences more precisely could improve how symptoms are measured in future studies.

The researchers are also investigating possible relationships between VSS, visual imagery and synaesthesia, a phenomenon in which stimulation of one sensory or cognitive pathway produces an additional involuntary experience.

Why does this matter?

A major challenge in VSS research is that there is currently no established objective diagnostic biomarker. Diagnosis relies on clinical criteria and the symptoms reported by patients.

Research that allows scientists to measure and compare aspects of visual perception could eventually contribute to more reliable assessment methods.

However, the VISIONS study is investigating visual processing, not testing a treatment.

Interested in participating?

The published study information invites adults with VSS and healthy volunteers who meet the eligibility criteria.

Participation involves one visit of approximately 90 minutes in London. The researchers provide breaks between tasks, and participants can request additional breaks or stop if they feel uncomfortable.

The visual experiments may temporarily increase symptoms or cause eyestrain, dizziness or headaches in some participants.

According to the study information, participants receive £25 for their time. Anyone travelling from abroad should confirm whether recruitment remains open and whether travel expenses are covered before making arrangements.

Study information: VISIONS – King’s College London

Contact: vs-research@kcl.ac.uk

2. Minnesota: What happens when the visual system adapts to what we see?

University of Minnesota, United States

Another research project is examining a fundamental feature of vision: visual adaptation.

Our visual system does not respond to every stimulus in exactly the same way indefinitely. When we are exposed to certain visual patterns for an extended period, our perception and sensitivity can change.

This process helps scientists understand how the visual system responds to ongoing stimulation.

Researchers at the University of Minnesota want to investigate whether visual adaptation differs in people with VSS and how these differences relate to brain function.

The study combines behavioural assessments and visual experiments with functional MRI and magnetic resonance spectroscopy.

These techniques allow researchers to investigate both visual performance and aspects of brain activity and neurochemistry.

Why does this matter?

One possibility being investigated in VSS research is that persistent visual symptoms are associated with differences in the way visual signals are generated or processed.

Studying adaptation may help researchers test specific hypotheses about those processes.

Importantly, visual adaptation experiments do not automatically reveal why VSS develops. Researchers must establish whether any observed differences are specific to VSS, reproducible and meaningfully related to symptoms.

The study is therefore primarily aimed at understanding mechanisms rather than offering symptom relief.

Interested in participating?

The University of Minnesota currently lists the study as recruiting.

The research includes adults with VSS aged 18–60 who meet additional health and eligibility requirements.

However, geographical restrictions apply to the VSS participant group. The published research information indicates that participants must live within approximately two hours of the study location.

For most international patients, participation is therefore unlikely to be feasible.

Study information: University of Minnesota – Visual Perception in Visual Snow Syndrome

Contact: schallmolab@umn.edu

3. London: Could VSS have a measurable neurological signature?

King’s College London, United Kingdom

While some studies are recruiting participants, others have reached an important stage: data collection is complete, and researchers are now analysing their findings.

One such project is being conducted at King’s College London by a research group involving Dr Francesca Puledda, Professor Peter Goadsby and their colleagues.

The team is using transcranial magnetic stimulation combined with electroencephalography (TMS-EEG) to investigate how the brain responds to stimulation.

TMS delivers magnetic pulses to targeted areas of the brain, while EEG records the resulting electrical activity.

Researchers have collected data from three groups: people with VSS, people with migraine and healthy participants.

According to the research update published in August 2026, data collection has been completed. Analysis is underway, with a scientific publication planned for submission in late 2026 or early 2027.

Why does this matter?

VSS frequently occurs alongside migraine, but the two are distinct conditions.

Researchers want to determine whether VSS has a recognisable neurophysiological profile and whether that profile differs from patterns associated with migraine.

If reproducible differences are identified, they could contribute to the search for neurological biomarkers.

However, a potential biomarker would need to be validated in larger, independent patient groups before it could be considered useful in clinical practice.

The important development here is that the study has moved from data collection to analysis. Its findings have not yet been published, so no conclusions about the results can be drawn.

Research update: King’s College London – 2026 Research Report

4. What about GABA, glutamate and future treatment targets?

King’s College London, United Kingdom

Another research direction at King’s College London focuses on the balance between excitatory and inhibitory signalling in the brain.

Two neurotransmitters are of particular interest: glutamate, the brain’s principal excitatory neurotransmitter, and GABA, an important inhibitory neurotransmitter.

Researchers are investigating whether changes in these systems could contribute to the neurological mechanisms underlying VSS.

Using advanced 7-tesla MRI and magnetic resonance spectroscopy, the team aims to examine aspects of brain metabolism and neurotransmitter concentrations.

According to the August 2026 research update, protocols have been finalised, pilot data have been collected and ethical approval is being pursued.

The broader research programme also includes a pharmacological component designed to investigate how changes in GABA-related signalling affect brain activity and symptoms.

Why does this matter?

If researchers identify reproducible abnormalities in particular neurotransmitter systems, these findings could eventually inform the development of more targeted treatment studies.

But there is an important distinction between identifying a possible biological mechanism and demonstrating that a medication can improve symptoms.

Even if altered GABA or glutamate signalling is observed, this would not establish that medications acting on these systems are effective or safe treatments for VSS.

The planned pharmacological research is intended to investigate mechanisms, not to establish a new treatment.

Research update: King’s College London – Research Programme

5. Switzerland: Advanced MRI research remains open to participants

University of Zurich, Switzerland

Not every relevant study is newly launched. Some longer-running projects remain important because they continue to investigate unanswered questions.

In Zurich, researchers are using high-field MRI to study neurological conditions including migraine, epilepsy and VSS.

The project uses advanced imaging methods to examine brain structure, function and other measurable characteristics.

Comparing different neurological conditions may help researchers determine which findings are shared and which could be more specific to VSS.

What is the current status?

The study was first registered in 2022 and is therefore not a new research project from 2026.

Nevertheless, it remains listed as recruiting in recent research registry information.

That makes it potentially relevant to patients interested in participating, although the availability of places specifically for people with VSS must be confirmed with the research team.

The study involves in-person assessments in Switzerland. International participants should ask about eligibility, the number of visits required and possible reimbursement of expenses before considering travel.

Study information: ClinicalTrials.gov – NCT05524493

Other Research Worth Following

Not every registered or announced project represents a new development.

For example, a randomised controlled trial investigating MBCT-vision, an adapted mindfulness-based programme for people with VSS, remains listed as not yet recruiting. However, its public registration has not been updated since August 2023.

Without more recent confirmation from the researchers, it would be misleading to present this as a newly available participation opportunity.

The study is designed to investigate whether an eight-week programme can affect perceived visual symptom severity and daily functioning. It does not assume that VSS has a psychological cause.

MBCT-vision – ClinicalTrials.gov

Genetic research is another area to watch. King’s College London is working towards incorporating VSS-related questions into TwinsUK, a major British twin research cohort.

Such research could eventually help clarify the contributions of genetic and environmental factors. According to the 2026 research update, the project is still progressing through approval procedures.

These projects remain relevant, but their current stage should not be confused with confirmed new findings or open recruitment.

Want to Participate in VSS Research? Here’s What You Should Know

Participating in research can be a valuable way to contribute to scientific understanding, even when a study does not offer treatment.

However, the practical requirements deserve careful consideration, particularly for people whose symptoms affect their ability to travel or tolerate visually demanding environments.

Before applying, consider the following questions:

  • Is the study genuinely recruiting? Public registries are not always updated immediately. Contact the research team to confirm that places are available.
  • Can you participate from your country? Some studies accept international participants, while others have geographical restrictions.
  • How many visits are required? A single appointment may be manageable for some patients, while repeated international travel may not be.
  • What will participation involve? Ask about bright or moving visual stimuli, MRI scans, possible symptom aggravation and opportunities for breaks.
  • Are expenses covered? A participation payment does not necessarily include travel or accommodation.
  • Is it a treatment study? Many VSS projects investigate neurological mechanisms rather than testing therapies.

For patients with severe symptoms, it is also reasonable to ask whether adjustments are available, such as additional rest periods, reduced sensory stimulation or remote completion of certain assessments.

Participation should be based on informed consent, and patients should never feel obliged to take part if the demands are beyond their capabilities.

Where can you find more studies?

Search ClinicalTrials.gov for Visual Snow Syndrome

ClinicalTrials.gov provides information about registered studies, including their objectives, locations, eligibility criteria and reported recruitment status.

Keep in mind that a study appearing in a register does not necessarily mean it is currently accepting new participants.

What Would Meaningful Progress Actually Look Like?

The growing range of VSS research methods is encouraging, but scientific progress should not be measured simply by the number of projects underway.

Several important questions remain.

Can researchers identify neurological findings that consistently distinguish VSS from migraine and other conditions? Can subjective visual symptoms be measured reliably enough to evaluate changes over time? And if a particular brain mechanism is identified, can influencing it produce a meaningful and lasting improvement in patients’ lives?

These questions matter because understanding a neurological difference is not the same as establishing its cause. Likewise, changing brain activity through an experimental intervention does not automatically demonstrate clinical benefit.

For research findings to become useful in healthcare, they must be reproducible, independently validated and shown to have practical significance.

The developments highlighted in this article illustrate different stages of that process. Some researchers are refining methods to measure visual perception. Others are analysing neurological data or investigating potential biological mechanisms. A smaller number of projects are exploring interventions, but reliable evidence for effective VSS treatments remains limited.

The next major advance may not be a treatment itself. It could be a reliable way to measure the condition, identify meaningful differences between patients or determine which neurological mechanisms are most relevant.

Those discoveries would not immediately eliminate symptoms. But they could help answer a question that remains central to VSS research: which findings can eventually be translated into treatments that make a measurable difference to patients?

That is the progress worth watching.


Visual Snow Europe independently follows developments in Visual Snow Syndrome research, with particular attention to scientific evidence, clinical relevance and accessibility for patients.

Research information reviewed in November 2026. Recruitment statuses, study timelines and eligibility requirements may change. Patients should consult the original research sources and contact study teams directly before making participation arrangements.

Bringing Visual Snow Syndrome into the spotlight

Sept. 02, 2026: Living with Visual Snow Syndrome can be difficult to explain to others. Especially when the condition is still unfamiliar to many. By sharing personal experiences and stories in the media, we aim to make VSS more visible and better understood. Discover recent interviews and features about living with VSS and the work of Visual Snow Europe Foundation. Despite growing scientific knowledge about Visual Snow Syndrome, public awareness remains limited. Many people have never heard of VSS, misconceptions and misinformation are still widespread, and knowledge of the condition among healthcare professionals can vary considerably. For those living with VSS, this can make an already complex neurological condition even more difficult to navigate.

For Visual Snow Europe Foundation, this is why media attention matters. It is not about publicity for its own sake. It is about ensuring that a neurological condition which is still too often misunderstood, underestimated or simply unknown is taken seriously.

Every well-informed article, interview and personal story can contribute to that change. More people recognising the name is only the beginning. The real goal is greater understanding among the public, within healthcare and ultimately in the research and care available to people living with VSS.

In the Media

Libelle interview about Visual Snow Syndrome
Libelle

Maartje van Meijel about her life with Visual Snow Syndrome

In a personal interview with ‘Libelle’ (Dutch Magazine), Maartje van Meijel shares her experience of living with Visual Snow Syndrome, the impact of the condition, and the importance of raising awareness and recognition.

READ THE ARTICLE →
Hoofdzaken interview about Visual Snow Syndrome
Hoofdzaken

In conversation about Visual Snow Syndrome

In ‘Hoofdzaken’ (Dutch Magazine) Maartje van Meijel tells about her personal experiences with Visual Snow Syndrome and her efforts to raise awareness, increase understanding, and advance scientific research into VSS.

READ THE ARTICLE →
📣

Media & press

Are you a journalist, editor or programme maker interested in covering Visual Snow Syndrome? Visual Snow Europe Foundation is happy to provide background information and connect you with relevant contacts. Please contact us at: info@visualsnoweurope.com .

Recent study strengthens evidence for VSS

August 11, 2026 – Researchers identify measurable differences in brain activity that could help pave the way for future biomarkers and more targeted treatments. A new study published in The Journal of Headache and Pain provides further evidence that Visual Snow Syndrome (VSS) is a measurable neurological disorder. Using electroencephalography (EEG), researchers identified characteristic patterns of brain activity that distinguish people with VSS not only from healthy individuals, but also from people with migraine alone.

Although the study does not introduce a new treatment, it offers important insights into how the brains of people with VSS process visual information. It also represents another step towards developing objective biomarkers, which may one day support diagnosis and improve future treatment research.


🔑 Key Takeaways

  • 🧠 Researchers identified measurable differences in brain activity in people with Visual Snow Syndrome.
  • 🎯 The findings could not be explained by migraine alone, supporting VSS as a distinct neurological disorder.
  • 🌐 The study suggests that VSS involves multiple interconnected brain networks, rather than only the visual cortex.
  • 📊 Machine learning distinguished people with VSS from healthy participants with approximately 80% accuracy.
  • 🔬 The findings may contribute to the development of objective biomarkers and more targeted treatments in the future.

What did the researchers investigate?

The researchers compared three groups of participants:

  • 30 people with Visual Snow Syndrome
  • 45 people with migraine without VSS
  • 47 healthy control participants

Brain activity was recorded using electroencephalography (EEG) while participants rested with their eyes closed. The researchers then analysed the recordings using advanced signal analysis and machine learning techniques to determine whether VSS has its own unique pattern of brain activity.


What did they find?

The study found that people with Visual Snow Syndrome showed distinct patterns of brain activity compared with both healthy individuals and people with migraine alone.

The most pronounced differences were found in brain regions involved in:

  • visual processing;
  • attention;
  • sensory filtering;
  • spatial perception;
  • multisensory integration.

Rather than affecting only the visual cortex, the findings suggest that multiple interconnected brain networks are involved in VSS.


More than a visual disorder

One of the most important findings is that the abnormalities were not limited to the visual cortex.

Instead, the researchers found changes in brain networks responsible for filtering incoming sensory information, directing attention and integrating visual input. This supports the growing theory that Visual Snow Syndrome is a brain network disorder, rather than simply a disorder of vision itself.

This may also help explain why many people with VSS experience symptoms beyond visual snow, including:

  • photophobia (light sensitivity);
  • palinopsia (persistent afterimages);
  • sensory overload;
  • difficulty coping with visually busy environments.

The researchers suggest that the brain may struggle to suppress irrelevant visual information, allowing unnecessary sensory input to remain in conscious awareness.


The parietal cortex may play a key role

One of the most interesting findings was the repeated involvement of the parietal cortex, a brain region responsible for attention, sensory integration and spatial awareness.

According to the researchers, this area may play a central role in the underlying mechanisms of VSS and could become an important target for future research into potential treatments.

Although no effective treatment has yet been established, identifying the brain networks involved represents an important step towards developing more targeted therapies.


Migraine alone does not explain the findings

Migraine is common among people with Visual Snow Syndrome, making it difficult to determine whether previous findings were actually caused by migraine rather than VSS itself.

To address this, the researchers specifically compared people with:

  • Visual Snow Syndrome with migraine
  • Migraine without Visual Snow Syndrome

Even after accounting for migraine, they still found clear differences in brain activity.

This provides further evidence that Visual Snow Syndrome has its own distinct neurological signature, rather than simply representing a form of migraine.


Why are alpha brain waves important?

One of the most consistent findings involved changes in alpha oscillations, a normal pattern of brain activity.

Alpha brain waves play an important role in:

  • filtering irrelevant sensory information;
  • directing visual attention;
  • suppressing unnecessary visual input.

The researchers believe that disturbances in these rhythms may contribute to the persistent visual phenomena experienced by people with VSS.

This could help explain why many patients describe feeling unable to “filter out” visual information or becoming overwhelmed by visually complex environments.


Machine learning successfully identified VSS

The researchers also used machine learning to analyse the EEG recordings.

Remarkably, the computer models were able to distinguish people with Visual Snow Syndrome from healthy participants with an accuracy of approximately 80%. They could also differentiate people with VSS from those with migraine alone.

Although this is not yet suitable as a diagnostic test, it demonstrates that VSS has measurable neurological characteristics that can be detected objectively.

This is an important development because objective biomarkers may eventually support diagnosis and enable future treatments to be evaluated more accurately.


What does this mean for future treatments?

The study does not demonstrate that any treatment currently works for Visual Snow Syndrome.

However, the findings point towards several promising areas for future research, including:

  • neuromodulation techniques such as transcranial magnetic stimulation (TMS);
  • neurofeedback;
  • therapies aimed at restoring normal brain rhythms;
  • treatments targeting inhibitory neurotransmitter systems, such as GABA.

It is important to note that these approaches remain experimental and require considerably more research before they can be recommended for clinical use.


What does this mean for people with VSS?

While this study does not provide an immediate new treatment, it adds to the growing body of evidence that Visual Snow Syndrome is associated with measurable changes in brain function.

For people living with VSS, this is another important step towards greater scientific understanding and recognition of the condition.

For clinicians and researchers, the findings contribute to the search for reliable biomarkers and improve our understanding of the neurological mechanisms underlying VSS.

Although there is still no proven treatment, studies like this continue to move the field forward and bring researchers closer to objective diagnostic tools and, ultimately, more targeted therapies.


Conclusion

This study provides further evidence that Visual Snow Syndrome is a distinct neurological brain network disorder involving multiple regions responsible for visual processing, attention and sensory integration.

Importantly, these abnormalities could not be explained by migraine alone, reinforcing the growing evidence that VSS is an independent neurological condition.

Perhaps the most significant aspect of this study is that it demonstrates objective, measurable differences in brain activity. As research continues, findings like these may help pave the way for reliable biomarkers, improve future clinical trials and support the development of more targeted treatments for people living with Visual Snow Syndrome.


Reference

Hsiao F-J, Puledda F, Chen W-T, et al. (2026). Unmasking the Noise: Aberrant Cortical Oscillations in Visual Snow Syndrome. The Journal of Headache and Pain. Published online 15 April 2026.

Frank’s experience with NORT, vestibular therapy and FL-41 glasses

Aug. 11, 2026: What treatments or tools may help people living with Visual Snow Syndrome (VSS)? This is a question we receive on a regular basis. Unfortunately, there is currently no proven treatment that cures VSS. However, some patients choose to try different therapies or supportive tools to see whether they can reduce certain symptoms or make them easier to manage.

In this article, Frank shares his personal experiences with Neuro-Optometric Rehabilitation Therapy (NORT), vestibular therapy, and FL-41 glasses. It is important to emphasise that this is a personal experience. The effects of treatments can vary considerably from one person to another. What improves symptoms for one individual may have little or no effect for someone else, and some people may even find certain treatments difficult to tolerate.

The Visual Snow Europe Foundation shares this article solely to inform patients about different approaches that are currently being explored or used. The information provided does not constitute medical advice and should not be interpreted as a recommendation or guarantee of effectiveness. Always discuss treatment options with your treating physician or another qualified healthcare professional.


Frank’s experience with NORT

“A year ago, I developed my first symptoms of Visual Snow. Unfortunately, these symptoms have continued to worsen ever since. At first, I wasn’t sure whether NORT would be worthwhile for me.”

Four months ago, Frank started NORT. The treatment is not inexpensive: the complete programme cost him approximately €3,000 and typically lasts between six and nine months.

The programme began with an explanation of visual processing.

“According to my clinician, people without Visual Snow use approximately 10–20% of their brain’s processing capacity for vision, whereas in people with Visual Snow this may increase to around 50%. They explained that visual processing forms the first layer of cognitive processing. When disruptions occur at this level, secondary processing difficulties may arise, such as tinnitus, fatigue or – in my case – insomnia.”

Unlike what Frank had read online about prism lenses and special glasses, his treatment was entirely computer-based.

“We started with a baseline assessment, which showed that my eyes were not working together optimally. Using the Visual Edge programme, we worked on improving this. The training can be done at home and involves a fairly intensive schedule of 30 minutes every other day on your laptop. The exercises include contrast training, memory exercises, saccades, convergence and divergence exercises, depth perception, and combination tasks. Symptoms can temporarily worsen during training, but fortunately that did not happen in my case. Every six weeks, a new assessment is carried out at the clinic. During the first six weeks, I achieved a 16% improvement, which was above average.”

After eighteen weeks, two additional exercises were introduced: NeuroTracker and Dynavision. These are completed once a week at the clinic and are designed to improve the brain’s processing speed by stimulating new neural connections. According to Frank’s clinician, the exercises may also help move the visual snow and floaters further into the background, as the brain learns to prioritise other information.

“After these sessions, I often felt somewhat ‘foggy,’ and my sleep was almost non-existent during those days. With NeuroTracker, you wear 3D glasses while looking at a field of moving tennis balls. You have to keep track of the balls and identify which ones were highlighted at the beginning of the exercise (see photo). There are several difficulty levels, and sometimes you also have to memorise additional information, such as a shopping list, while completing the task. Over a twelve-week period, my processing speed increased from 1.3 to 2.9. I still have six weeks of training left, so there may be further improvements.”

Dynavision consists of a board with red and green illuminated buttons that light up randomly. The goal is to press them as quickly as possible. This exercise is designed to train peripheral awareness and reaction speed. Both exercises resulted in measurable improvements in processing speed. However, Frank also experienced mild headaches and insomnia for several days afterwards.

Did it help?

“I noticed that I process sensory input much better, particularly in busy public environments. I also find it easier to absorb new information at work. Unfortunately, my visual snow itself and my tinnitus have become worse, although this may be a temporary effect related to reducing my medication. I have therefore not experienced any improvement in those symptoms. My perception of floaters has also remained unchanged.

Personally, I am glad that I completed the programme. The improvement in sensory processing has helped me in family life, at work, and in social situations. At the same time, it remains an expensive treatment if you have to pay for it yourself. My experience is, of course, entirely personal, and I cannot say whether this treatment is suitable for others or whether they would experience similar results.”


Frank’s experience with vestibular therapy

“When my Visual Snow symptoms first began to develop, it started with floaters. A few months later, it felt as though my vision was moving, as if I had drunk half a crate of beer. I also noticed line patterns vibrating and overlapping each other. I underwent an MRI scan and saw an ENT specialist, but nothing abnormal was found. The MRI was normal, and no further action was taken regarding my symptoms.

After discussing my symptoms with my GP, vestibular therapy was suggested. This therapy is provided by specialised physiotherapists and involves training for approximately five minutes, three times a day. The exercises are simple to perform at home.”


Example exercises

1. Eye and head coordination

  • Place two sticky notes with a dot at eye level on a wall, approximately 30 cm apart, and stand about half a metre away.
  • Move only your eyes from one dot to the other without moving your head.
  • Once your eyes reach the dot, smoothly move your head in the same direction.

2. Smooth pursuit exercise

  • Hold your thumb up approximately 50 cm in front of your face.
  • Move your thumb in random directions.
  • Follow the movement using only your eyes while keeping your head still.

3. Increase the challenge

  • Perform the first exercise against a visually busy background, such as a checkerboard pattern, or while standing on one leg.

Did it help?

“For me, yes. Within a few weeks, my vision felt much more stable. Again, this is purely my personal experience and does not indicate how effective it may be for others.”


Frank’s experience with FL-41 glasses

FL-41 glasses are often mentioned as one of the first supportive tools for people with Visual Snow. However, not all FL-41 glasses are the same: their quality varies considerably, and they do not work for everyone. In some countries, colorimeters are used to precisely determine which filter works best for each individual. Frank explains that he has not yet been able to find this option in either the Netherlands or Belgium.

“After contacting several optometrists, I have not yet found an option for prescription FL-41 lenses. Prices for FL-41 glasses range from approximately €40 to €170, and not all models are suitable to wear over prescription glasses.”

What are the differences between FL-41 glasses?

“First of all, not every FL-41 model is suitable as an over-glasses fit. In addition, there are significant differences in filter quality. Broadly speaking, there are three shades:

  • Light pink — mild filter
  • Medium pink — standard FL-41
  • Dark pink / red — stronger filter, which can sometimes be too intense.

The brain responds differently to these shades. Some people actually experience more visual noise when using a stronger tint, so it is important to determine which works best for you.

The original FL-41 tint primarily filters light within the 480–520 nm (blue-green) wavelength range. Many lower-cost glasses simply use a general pink tint that does not effectively filter these wavelengths. Light transmission also varies considerably: some lenses allow around 80% of light to pass through, while others allow only about 50%. There are also glasses marketed as ‘FL-41’ that simply have a cosmetic pink tint without using the genuine filter.

It is also worth remembering that light plays an important role in regulating the body’s sleep-wake cycle. For that reason, wearing FL-41 glasses throughout the entire day may not be appropriate for everyone.”

Other differences between FL-41 glasses include:

  • the level of polarisation;
  • the presence of an anti-reflective coating;
  • the number of filter layers.

Visio

“At Koninklijke Visio* (depending on the location), you can borrow a pair of Multilens FL-41 glasses for one week to try them out. I eventually decided to purchase a pair myself. They do not directly reduce my visual snow, but they do reduce my sensory overload. This is particularly helpful when trying to fall asleep. I wear them while working and when watching television.

Again, this is only my personal experience. FL-41 glasses do not work for everyone, and the degree of benefit varies from person to person. If you are considering trying FL-41 glasses, it may be worth asking whether a trial period is available before purchasing a pair.”


*Koninklijke Visio: a Dutch organisation specialising in visual rehabilitation and support. Although VSS is a neurological condition rather than an eye disease, some people with VSS may benefit from advice on visual aids or filters to help manage certain symptoms.

Visual Snow: a new step in measuring symptom impact

December 13, 2025 – For people living with Visual Snow (Syndrome), it is often difficult to put into words how much impact their symptoms have. Not just that the symptoms are there, but what they do to everyday functioning, concentration, sleep, and mental wellbeing. This is precisely what makes it so hard to receive appropriate care or to assess treatments fairly.

A new international study, published in Frontiers in Neurology, takes an important step forward in this area. The study evaluates an updated questionnaire: the Colorado Visual Snow Survey 2.0 (CVSS 2.0). This survey is designed to systematically capture which VSS symptoms a person experiences, how severe they are, and how strongly they affect daily life.

Why is this important?

Visual Snow Syndrome has only relatively recently been recognised as a neurological condition. Until now, there have been very few reliable tools that allow patients to report their symptoms and limitations in a way that is also useful for research and clinical care. This is a major problem: without proper measurement tools, it is almost impossible to test treatments or to objectively track improvement—or deterioration—over time.

The CVSS 2.0 aims to fill this gap.

What exactly is measured?

The survey does not focus solely on visual static (“snow”), but looks at a broader range of symptoms that many people with VSS recognise, including:

  • afterimages and visual trails
  • blue field entoptic phenomenon (moving light dots against a blue background)
  • floaters
  • night vision difficulties
  • tinnitus
  • and non-visual symptoms such as depersonalisation/derealisation, anxiety and low mood (note: anxiety and low mood as a consequence of symptoms)

For each symptom, four aspects are assessed:
its intensity, how much it interferes with screen use, how much it interferes with everyday visual environments, and to what extent it limits daily activities. This last aspect is crucial, as it highlights that VSS is not only a perceptual issue, but a condition that can profoundly affect daily functioning.

What were the findings?

The researchers compared people with Visual Snow to a control group without VSS. The results were clear:

The CVSS 2.0 strongly differentiated between people with and without VSS. People with a formal diagnosis and those without a diagnosis (but with clear VSS symptoms) scored almost identically. This reinforces what many patients already know: the absence of an official diagnosis says very little about the severity of symptoms.

In addition to visual static, the strongest predictors of Visual Snow were night vision problems, blue field entoptic phenomenon, afterimages, and tinnitus. Notably, tinnitus scored highly as a distinguishing symptom, even though it is not currently part of the official international diagnostic criteria. The authors suggest that this may warrant reconsideration.

Mental health symptoms are not secondary

The study also pays attention to symptoms such as depersonalisation/derealisation, anxiety and low mood. These were clearly more frequent and more severe in people with VSS than in controls. The researchers stress that these symptoms deserve serious attention in the care of VSS patients—not as a “psychological explanation” for the condition, but as part of the overall disease burden and quality of life.

In other words, mental health symptoms are not peripheral; they may be a logical consequence of prolonged neurological overload and continuous visual disturbance.

What does this mean for patients?

This study does not offer a treatment or a direct solution. However, it does provide an important foundation. Better measurement tools are essential to:

  • fairly evaluate treatments,
  • make the severity of symptoms visible to clinicians,
  • and finally determine whether interventions genuinely help.

For patients, this may represent a step towards greater recognition, better communication with healthcare professionals, and ultimately improved care.

Why Visual Snow Europe is sharing this

At Visual Snow Europe, we believe it is essential that research does not remain confined to academic journals, but is shared in a way that is accessible to the people it concerns. Studies like this show that Visual Snow Syndrome is being investigated in an increasingly serious and systematic manner—and that patient experience plays a central role in this progress.

We remain committed to raising awareness, improving diagnostics, and supporting research that reflects the real-life experiences of people living with Visual Snow Syndrome.

More information about this study can be found here.
Visual Snow Europe Foundation was not involved in this research.

VSS officially recognized with ICD-11 code

January 24, 2025 – Visual Snow Syndrome (VSS) has now been officially recognized with a unique code in the eleventh edition of the International Classification of Diseases (ICD-11) by the World Health Organization (WHO). This significant milestone is the result of collaborative efforts by the Visual Snow Initiative (VSI), led by founder Sierra Domb, in partnership with prominent neurologists such as Dr. Peter Goadsby and Dr. Owen White.

The assignment of an ICD code to VSS has far-reaching positive implications for both patients and the global medical community. It acknowledges VSS as a legitimate neurological disorder, which will enhance the accuracy of diagnosis and treatment. Furthermore, this recognition enables healthcare services related to VSS to become eligible for insurance coverage and financial support. It will also stimulate further research into VSS, potentially leading to better treatment methods and a deeper understanding of the condition.

Beginning in 2025, Visual Snow Syndrome and its associated symptom, Visual Snow, will be officially included in the ICD-11. This acknowledgment marks a turning point for everyone affected by VSS and offers hope for improved care and understanding in the future.

New study possible medication VSS

September 17, 2024 – A new study investigating the effectiveness and safety of medication for the treatment of Visual Snow Syndrome (VSS) is being investigated. The goal of this study is to discover whether pharmacological treatment, or medication, can safely address the specific deficits associated with VSS, alleviate visual symptoms and thereby improve patients’ quality of life.

This groundbreaking research is a collaboration between Visual Snow Initiative and well-known VSS neurologists, other Dr. Peter Goadsby, Dr. Francesca Puledda, Dr. Christoph Schankin and Sarah Aeschlimann. The identification of medications with therapeutic potential to treat VSS could represent a breakthrough in clinical practice. If researchers succeed in identifying a medication that proves to be effective, it could form the basis for the first effective pharmacological treatment options for VSS patients.

This new clinical trial will take place at the University Hospital of Bern, Department of Neurology, in Switzerland. After submission of an ethics application and approval by Swissmedic, recruitment for the study will begin. The expected completion of the study is July 2025. Administration of the medication and possible side effects will be carefully monitored by VSS researchers with expertise in the condition to ensure the safety of participants. They will regularly measure the severity of VSS, reduction in symptoms, quality of life and any side effects.

Despite intensive efforts, the development of effective pharmacological therapies for VSS has remained a challenge. Medications tested to date were considered ineffective by researchers, with symptoms usually worsening or no changes occurring. Although some individuals with VSS have reported that certain medications have helped them, there is no clinical evidence to support an effective pharmacological treatment for VSS. Researchers needed more insights into the cause and pathophysiology of VSS before they could identify possible targeted and effective treatments.

Recent studies had revealed new crucial information about the cause, pathophysiology, symptomatology and mechanisms of Visual Snow Syndrome as a network disorder. By comparing the distribution of receptors in different brain regions and functional connectivity patterns, a recent study was able to identify changes in the serotonergic and glutamatergic neurotransmitter systems that may contribute to the pathophysiology of VSS. In this new clinical trial, researchers will investigate the potential effectiveness and safety of medications that target the specific deficits associated with VSS.

We’ll keep you up to date as soon as more news is known.

New Research by Prof. dr. Schankin in Inselspital

May 7, 2024 –

Dr. Schankin and Dr. Klein of Inselspital Bern (Switzerland) will initiate a new study on neuromodulation for VSS. This research investigates how transcranial alternating current stimulation (tACS) can modulate overactive neural networks in the brain, potentially leading to new treatment options for VSS. Dr. Schankin and Dr. Klein’s techniques are aimed at reducing several common VSS symptoms, including visual snow/static, palinopsia, entoptic
symptoms, photophobia and nyctalopia.

The underlying idea behind VSS is that multiple neural networks in the brain remain overactive, bombarding the visual system with excess information. TACS, however, offers the ability to modulate these networks. Dr. Schankin and Dr. Klein’s primary goal is to pinpoint the specific areas of the brain where something is not functioning properly. To accomplish this, they are combining several diagnostic markers with a treatment-oriented methodology.

Their research will begin with a comprehensive visual test, MRI and electroencephalogram (EEG) measurements. Dr. Schankin and Dr. Klein are particularly interested in observing how this stimulation affects VSS symptoms, how it affects performance on tasks and whether there are changes in EEG patterns in patients with VSS.

Promising Discovery: Altered Neuroactivity in VSS

August 11, 2023: Researchers from King’s College London are sharing their latest discovery: The activity of glutamate and serotonin differs in individuals with VSS compared to those without the condition, potentially triggering the identification of biomarkers and fostering hope for future pharmacological treatments.

Visual Snow Syndrome (VSS) has long mystified researchers due to its poorly understood neuropharmacological underpinnings. Seeking to demystify this perplexing condition, a pioneering study harnessed the power of cutting-edge technology. By combining receptor target maps with functional magnetic resonance imaging (fMRI) data at rest, the goal was to decipher which neurotransmitters might be orchestrating the brain circuits linked to VSS.

The study employed a novel technique called Receptor-Enriched Analysis of Functional Connectivity by Targets (REACT). This innovative approach delved into the intricate functional networks influenced by five distinct neurotransmitter systems. Participants included individuals with VSS (n = 24), healthy controls (HCs; n = 24), and migraine patients (MIG; n = 25, including 15 with migraine with aura [MwA]). REACT utilized receptor density templates for pivotal neurotransmitter receptors and transporters, such as noradrenaline, dopamine, serotonin, GABA-A, NMDA, 5HT1B, and 5HT2A. These templates facilitated the creation of personalized, voxel-level functional connectivity (FC) maps. These individualized maps were then meticulously compared across the three groups: HCs, MIG, and VSS.

Fascinating outcomes emerged from this exploration. Individuals grappling with VSS exhibited diminished FC within glutamatergic networks situated in the anterior cingulate cortex (ACC). This divergence was evident when juxtaposed with both HCs and patients with migraines. Moreover, a notable reduction in FC within serotoninergic networks surfaced in regions like the insula, temporal pole, and orbitofrontal cortex. These patterns mirrored observations made in individuals with migraine with aura. Of significant interest, VSS patients showcased reduced FC within networks rich in the 5HT2A receptor. These networks were primarily located in occipito-temporo-parietal association cortices. Subgroup analyses revealed that these alterations were not only independent of migraine influences but also akin to changes seen in patients with migraine with aura.

This study’s implications are far-reaching. It highlights the pivotal roles of glutamate and serotonin in rewiring brain connectivity, impacting domains associated with visual processing, salience detection, and emotional responses within the context of VSS. Importantly, altered serotonergic connectivity in VSS stands on its own, unrelated to migraines. Nonetheless, the striking resemblance to patterns seen in migraine with aura underscores a shared biological foundation between these distinct disorders.




(Source: ANN NEUROL 2023)